Abiopharma

🔍 Franklin Katherine F. (Executive)

Company: ESCALADE INC (ESCA)

Report Date: 2026-05-06

Detailed Transactions and Holdings:

• Acquired 2,250 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 32,829.78 | transaction_form_type: 4 | Footnotes: F1
• Acquired 2,150 shares of Common Stock (Direct)
  Date: 2026-05-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 34,979.78 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-06 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 223,842.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-06 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 309,213.00 | Footnotes: F3
• Acquired 5,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-06 | Code: A | Expires: 2028-05-06 | equity_swap_involved: 0 | shares_owned_after: 5,000.00 | transaction_form_type: 4 | Footnotes: F4, F5
• Sold 2,250 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-07 | Code: M | Expires: 2027-05-07 | equity_swap_involved: 0 | shares_owned_after: 2,250.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 2,150 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-08 | Code: M | Expires: 2026-05-08 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F7

Footnotes:

• F1: Restricted Stock Units (RSUs) converted into common stock on a one-for-one basis.
• F2: Ms. Franklin disclaims beneficial ownership in shares held by a revocable trust owned by her father, except to the extent of her pecuniary interest therein.
• F3: Ms. Franklin disclaims beneficial ownership in shares held by a revocable trust owned by her mother, except to the extent of her pecuniary interest therein.
• F4: Each Restricted Stock Unit (RSU) represents a right to receive one share of Escalade common stock pursuant to the Escalade, Incorporated 2017 Incentive Plan (the "Plan"). Shares will be delivered to the reporting person upon vesting of the applicable RSUs, unless the reporting person defers receipt.
• F5: On May 6, 2026, the reporting person was granted 5,000 RSUs pursuant to the Escalade 2017 Plan, of which one half will vest on May 6, 2027 and one half on May 6, 2028, provided that the reporting person remains a director of Escalade.
• F6: On May 7, 2025, the reporting person was granted 4,500 RSUs pursuant to the Escalade 2017 Plan, of which one half vested on May 7, 2026 and one half will vest on May 7, 2027, provided that the reporting person remains a director of Escalade.
• F7: On May 8, 2024, the reporting person was granted 4,300 RSUs pursuant to the Escalade 2017 Plan, of which 2,150 RSUs vested and settled on May 8, 2025 and the remaining 2,150 RSUs vested and settled on May 8, 2026.